Learn more about whether ACADIA Pharmaceuticals Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...

Acadia (ACAD) delivered earnings and revenue surprises of -10.53% and 1.79%, respectively, for the quarter ended December ...

Acadia is seeing solid growth from its two products on the market. Check out the analysis of ACAD stock following Q4 numbers ...

A former pharmaceutical executive traded on nonpublic information about an antipsychotic drug’s development, avoiding $1.3 ...

Full Year 2024 Results Key Financial Results Revenue: US$957.8m (up 32% from ...

Morgan Stanley assumed coverage of Acadia Pharmaceuticals (ACAD) with an Equal Weight rating and $20 price target The firm sees patent ...

HC Wainwright reiterated their buy rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a report ...

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report)‘s stock had its “equal weight” rating reaffirmed by investment analysts at Morgan Stanley in a report issued on Friday,Benzinga reports. They ...

Analysts have set 12-month price targets for ACADIA Pharmaceuticals, revealing an average target of $25.0, a high estimate of $28.00, and a low estimate of $20.00. A 2.91% drop is evident in the ...

Acadia Pharmaceuticals (ACAD) and Saniona announced the completion of the two originally planned cohorts in their Phase 1 ...

VP at Acadia Pharmaceuticals, pled guilty to insider trading, avoiding a $1.3M loss by illicitly selling shares ahead of a ...